VIARTIS

 

 

 PARKINSON'S DISEASE NEWS

 

 

 

 

 

7th June 2012 - News release

FIRST VACCINE FOR PARKINSON'S DISEASE

The first clinical trial for the development of a Parkinsonís Disease vaccine has been started by AFFiRiS AG. The vaccine called PD01A is directed against alpha-Synuclein, a protein considered by AFFiRis to cause the onset and progression of Parkinson's Disease. The vaccination aims to educate the immune system to generate antibodies directed against alpha-Synuclein. They believe that a reduction of the brainís alpha-Synuclein aggregates will have a beneficial impact on the progress of Parkinson's Disease. PD01A aims to accomplish that by the induction of antibodies that are targeting alpha-Synuclein, in order to neutralize its toxic impact.

The vaccine is currently being tested on people with Parkinsonís Disease in a Phase I trial. The clinical trial is taking place in Vienna and involves up to 32 patients. The primary purpose is to assess the safety and tolerability of PD01A. For more information go to AFFiRis.

The weakness in the theory on which the method is reliant is that a lot of people with Parkinson's Disease do not accumulate alpha-Synuclein. So there is none to get rid of. Most people that have an accumulation of alpha-Synuclein in the brain do not have Parkinson's Disease either, thereby proving that alpha-Synuclein is not the cause of Parkinson's Disease. For a printable version of this article click hereFor more current news go to Parkinson's Disease News.

 

E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new articles are added to Parkinson's Disease News,  please merely e-mail [email protected] with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Parkinson's Disease News details all significant new research, news reports, new books, and new resources concerning Parkinson's Disease and those medical disorders that often coincide with Parkinson's Disease. It is compiled from an analysis of  all newly published research, news reports, new clinical trials, all newly published books, and new web sites. A summary and analysis of the new research are provided,  as well as links to the complete abstracts and news reports

                                    

 

 
©2006-2012  Viartis
 
2015-09-04 03:08:15
 
[email protected]